-- Naofumi Kagami Named Site Head/General Manager
(BOTHELL, Washington, Sept. 24, 2019 PRNewswire=연합뉴스) AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today the appointment of Naofumi Kagami as Site Head/General Manager of the Chiba, Japan facility. Kagami-san will provide leadership and site management to ensure the continued execution of world-class contract development and manufacturing services. He will support the continuous growth of the Chiba facility while working closely with colleagues in Copenhagen, Heidelberg and Seattle to ensure the business leverages and integrates AGC Biologics combined global capabilities.
Kagami-san brings 25 years of industry experience to his role. Prior to joining AGC Biologics, he worked for Roche Diagnostics, Lonza and Sartorius Stedim in Japan in R&D, marketing and sales roles of increasing leadership responsibility for the life science and bio-manufacturing markets. He holds a Master of Science degree in Biochemistry and Biophysics from the University of Tokyo Graduate School.
"We are pleased to have Kagami-san, a standout leader within the Life Sciences industry, join our world class team at AGC Biologics," said Kasper Moller, AGC Biologics Chief Technology Officer. "The role of Site Head/General Manager of the Chiba facility is essential to our operation's expansion and growth. Kagami-san has the expertise and experience to lead our Chiba site in the growth and achievement of our stated goals and objectives.
About AGC Biologics
AGC Biologics is a leading global Contract Development and Manufacturing Organization (CDMO), with a strong commitment to deliver the highest standard of service to our clients and partners. AGC Biologics is the product of the convergence and integration of Asahi Glass Company (AGC) Bioscience, Biomeva GmbH, and CMC Biologics. The company currently employs more than 850 employees worldwide. Our extensive network spans three continents, with cGMP-compliant facilities in Seattle, WA; Copenhagen, Denmark; Heidelberg, Germany; and Chiba, Japan.
AGC Biologics offers deep industry expertise and unique customized services for the scale-up and cGMP manufacture of protein-based therapeutics; from pre-clinical to commercial production, for mammalian and microbial. Our integrated service offerings include cell line development, bioprocess development, formulation, analytical testing, antibody drug development and conjugation, cell banking and storage, and protein expression ― including our proprietary CHEF1(R) Expression System for mammalian production. Further information can be found at www.agcbio.com.
Source: AGC Biologics
[편집자 주] 본고는 자료 제공사에서 제공한 것으로, 연합뉴스는 내용에 대해 어떠한 편집도 하지 않았음을 밝혀 드립니다.
<저작권자(c) 연합뉴스, 무단 전재-재배포 금지> 2019/09/25 06:12 송고